



Press release |

IBA Signs a Contract for the New Proton Therapy Center of Cracow, Poland

IBA demonstrates its ability to make Proton Therapy accessible at lower costs

For immediate release – August 2, 2010

Louvain-la-Neuve, Belgium, August 2 , 2010 – IBA (Ion Beam Applications S.A.) announces today that The Henryk Niewodniczanski Institute of Nuclear Physics of the Polish Academy of Science (IFJ) adjudicated to IBA the supply of a cyclotron along with the essential technological equipments for the construction of the Bronowice Cyclotron Center (CCB – Centrum Cyklotronowe Bronowice), Cracow, Poland. This Proton Therapy center is composed of one clinical treatment room (fixed beam) and one research room. This constitutes the first stage of the development of the Polish National Centre for Hadron Radiotherapy (NCRH).

This public tender, covering the cyclotron, the technical equipment and the construction of the building, amounts to between 25 and 30 million Euros.

“An important factor in this selection was IBA’s unique expertise in the field of Proton Therapy and IBA’s contribution to recent breakthroughs in cyclotron technology demonstrated over the last few years, said Prof. Marek Jezabek, Director General of the IFJ.

“Winning this public tender underlines the recognition of IBA as an expert in developing the best Proton Therapy technologies and we are eager to start participating soon in developing IBA’s fifth clinical proton therapy center in Europe. We are honored to partner with the prestigious Polish Academy of Sciences to improve the way we fight cancer in Europe. We hope that additional rooms will be added to the current configuration of the center in the future to make this particularly efficient cancer therapy accessible to more patients.”, said Pierre Mottet, Chief Executive Officer of IBA.

The configuration that IBA will install for IFJ shows once more IBA’s commitment to make Proton Therapy ever more accessible. IBA demonstrates here its ability to provide expandable Proton Therapy centers at lower costs for the benefits of the patients worldwide.

IBA is committed to making proton therapy, the most accurate cancer treatment, available worldwide. Globally, IBA has sold 18 proton therapy centers, which represents over half of the clinical-based proton therapy facilities in the world.



Press release |

ABOUT IBA

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

Listed on the pan-European stock exchange Euronext, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com

Contact

IBA

Thomas Ralet

VP Corporate Communication

Tel.: +32 10 47 58 90

Email: InvestorRelations@iba-group.com